{"eventGroups":[{"description":"Group A: Subjects with Multiple Myeloma\n\n* Conditioning regimen, over a 7 day period, includes:\n* Melphalan 70-100 mg, Dexamethasone 4 mg IV push, Aprepitant 125 mg PO, Palonosetron 0.25 mg IV over 30 seconds, Aprepitant 80 mg PO, Dexamethasone 4 mg IV and Lorazepam 1 mg IV x 1 dose 30 minutes prior to stem cell infusion","id":"EG000","otherNumAffected":3,"otherNumAtRisk":9,"seriousNumAffected":0,"seriousNumAtRisk":9,"title":"Subjects With Multiple Myeloma"},{"description":"Group B: Subjects with Lymphoma\n\n* Conditioning regimen, over a 7 day period, includes: (BEAC)\n* BCNU 300 mg/m2 IV x 1,Cytarabine 100 mg/m2 IV BID, Etoposide 100 mg/m2 IV BID, administer after, Cyclophosphamide 35 mg/kg QD, Dexamethasone 4 mg IV push, Aprepitant 125 mg PO, Palonosetron 0.25 mg IV over 30 seconds, Aprepitant 80 mg PO, Lorazepam 1 mg IV x 1 dose 30 minutes prior to stem cell transplant","id":"EG001","otherNumAffected":2,"otherNumAtRisk":9,"seriousNumAffected":0,"seriousNumAtRisk":9,"title":"Patients With Lymphoma"}],"frequencyThreshold":"5","otherEvents":[{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":9,"numEvents":0},{"groupId":"EG001","numAffected":1,"numAtRisk":9,"numEvents":1}],"term":"Infection, Abdomen NOS"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":9,"numEvents":0},{"groupId":"EG001","numAffected":1,"numAtRisk":9,"numEvents":1}],"term":"Gastric Mucositis"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":9,"numEvents":0},{"groupId":"EG001","numAffected":1,"numAtRisk":9,"numEvents":1}],"term":"Gallbladder pain"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":9,"numEvents":1},{"groupId":"EG001","numAffected":1,"numAtRisk":9,"numEvents":1}],"term":"Febrile neutropenia"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":9,"numEvents":0},{"groupId":"EG001","numAffected":1,"numAtRisk":9,"numEvents":1}],"term":"Hyponatremia"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Cardiac disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":9,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":9,"numEvents":0}],"term":"Conduction disorder"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":9,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":9,"numEvents":0}],"term":"Infection, Catheter-related"}],"timeFrame":"Day +30"}